Funding This study was sponsored by Eli Lilly
Ask what diagnosis is being treated, what evidence supports the option, whether imaging or rehabilitation is needed, whether the source is legitimate, what risks apply to your health history, how progress will be measured, and what the plan is if symptoms do not improve
While these medications offer significant benefits for appropriate candidates, they are not suitable for everyone
The FDA collected 480 adverse event reports for compounded tirzepatide products as of April 2025
We offer guidance on managing stress, improving sleep, and adopting healthier habits
At the 12-month follow-up : 87.5% of patients reported significant relief defined as 50% reduction in baseline pain scores Mean VAS pain score dropped from 7.2 at baseline to 2.8 at 12 months KOOS (Knee Injury and Osteoarthritis Outcome Score) improved across all subscales: pain, symptoms, activities of daily living, sport/recreation, and quality of life No serious adverse events were reported across the treatment period The durability of the response at 12 months is particularly notable
